Recall for blood pressure medication losartan has expanded for a fifth time; the lead crisis in Newark is easing after significant filter results for water; allergists speak about the pros and cons of the potential first peanut allergy treatment.
The recall of common blood pressure medication losartan has grown for a fifth time after manufacturer Torrent Pharmaceuticals uncovered a possibly carcinogenic impurity in more batches of the drug, according to USA Today. The FDA said that 3 lots of losartan potassium tablets and 2 additional lots of losartan potassium/hydrochlorothiazide tablets were under recall for levels of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) over the daily recommendation. As the FDA described NMBA as a “potential human carcinogen,” these heightened levels reveal a health hazard for users. Multiple blood pressure medications have been recalled since last July, such as valsartan, losartan, and irbesartan due to these levels of NMBA, as well as levels of Nitrosodimethylamine, and N-Nitrosodiethylamine.
Newark officials announced Monday that thousands of water filters given to residents had significantly reduced lead in drinking water, according to The New York Times. The filters were shown to be 97% effective in reducing lead levels to below the federally acceptable standard, based off testing done jointly by city, state, and federal officials. Back in August, Newark began distributing bottled water amid unsafe levels of lead in the drinking water. Since 3% of the results showed rates above the level set by the state, bottled water will still remain available to citizens.
An oral immunotherapy for peanut allergy control named Palforzia was recommended for approval by an FDA committee earlier this month, which has some allergists arguing it is beneficial and others saying it is unnecessary, according to NPR. If approved, it would be the nation’s first FDA-approved treatment for food allergies. The oral immunotherapy involves ingesting gradually increasing small doses of peanut protein to ameliorate the immune system’s overreaction to peanuts. Some allergists note this is already underway in current practice; these allergists also perceive issues in the pricing of 1-year’s supply of Palforzia that can potentially run to $4200 per patient. Not all allergists are opposed to the therapy, however, as some stressed the importance of distributing a standardized product for more predictable and safer results.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles
March 28th 2024In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.
Read More
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More